Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2

Figure 3

(a) Comparison of the first day S1P level of blood of K6PC-5 treated and nontreated rats. (b) Comparison of last day S1P level of blood of K6PC-5 treated and nontreated rats (). (c) Comparison of last day S1P level of cardiac tissue of K6PC-5 treated and nontreated rats (). (d) Comparison of first day S1P level of blood of healthy and diabetic rats. (e) Comparison of last day S1P level of blood of healthy and diabetic rats (). (f) Comparison of last day S1P level of cardiac tissue of healthy and diabetic rats (). (g) Comparison of blood samples’ S1P level of the first day of CS, S50, S100, S200, CD, D50, D100, and D200 groups. (h) Comparison of blood samples’ S1P level of last day of CS, S50, S100, S200, CD, D50, D100, and D200 groups (). (i) Comparison of cardiac tissue samples’ S1P level of last day of CS, S50, S100, S200, CD, D50, D100, and D200 groups ().

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)